TargetPotassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Affinity DataIC50: 15.8nMAssay Description:Inhibition of human HCN1 heterologously expressed in HEK-293 cells after 30 mins by VIPR assayMore data for this Ligand-Target Pair
TargetPotassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Affinity DataIC50: 31.6nMAssay Description:Inhibition of human HCN1 heterologously expressed in HEK-293 cells after 30 mins by VIPR assayMore data for this Ligand-Target Pair
TargetPotassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Affinity DataIC50: 31.6nMAssay Description:Inhibition of human HCN4 heterologously expressed in HEK-293 cells after 30 mins by VIPR assayMore data for this Ligand-Target Pair
TargetPotassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Affinity DataIC50: 31.6nMAssay Description:Inhibition of human HCN1 heterologously expressed in HEK-293 cells after 30 mins by VIPR assayMore data for this Ligand-Target Pair
TargetPotassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Affinity DataIC50: 50.1nMAssay Description:Inhibition of human HCN1 heterologously expressed in HEK-293 cells after 30 mins by VIPR assayMore data for this Ligand-Target Pair
TargetPotassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Affinity DataIC50: 79.4nMAssay Description:Inhibition of human HCN1 heterologously expressed in HEK-293 cells after 30 mins by VIPR assayMore data for this Ligand-Target Pair
TargetPotassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Affinity DataIC50: 126nMAssay Description:Inhibition of human HCN1 heterologously expressed in HEK-293 cells after 30 mins by VIPR assayMore data for this Ligand-Target Pair
TargetPotassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Affinity DataIC50: 158nMAssay Description:Inhibition of human HCN4 heterologously expressed in HEK-293 cells after 30 mins by VIPR assayMore data for this Ligand-Target Pair
TargetPotassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Affinity DataIC50: 158nMAssay Description:Inhibition of human HCN1 heterologously expressed in HEK-293 cells after 30 mins by VIPR assayMore data for this Ligand-Target Pair
TargetPotassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Affinity DataIC50: 200nMAssay Description:Inhibition of human HCN1 heterologously expressed in HEK-293 cells after 30 mins by VIPR assayMore data for this Ligand-Target Pair
TargetPotassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Affinity DataIC50: 251nMAssay Description:Inhibition of human HCN1 heterologously expressed in HEK-293 cells after 30 mins by VIPR assayMore data for this Ligand-Target Pair
TargetPotassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Affinity DataIC50: 316nMAssay Description:Inhibition of human HCN4 heterologously expressed in HEK-293 cells after 30 mins by VIPR assayMore data for this Ligand-Target Pair
TargetPotassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Affinity DataIC50: 316nMAssay Description:Inhibition of human HCN1 heterologously expressed in HEK-293 cells after 30 mins by VIPR assayMore data for this Ligand-Target Pair
TargetPotassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Affinity DataIC50: 316nMAssay Description:Inhibition of human HCN4 heterologously expressed in HEK-293 cells after 30 mins by VIPR assayMore data for this Ligand-Target Pair
TargetPotassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Affinity DataIC50: 398nMAssay Description:Inhibition of human HCN1 heterologously expressed in HEK-293 cells after 30 mins by VIPR assayMore data for this Ligand-Target Pair
TargetPotassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Affinity DataIC50: 398nMAssay Description:Inhibition of human HCN1 heterologously expressed in HEK-293 cells after 30 mins by VIPR assayMore data for this Ligand-Target Pair
TargetPotassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Affinity DataIC50: 398nMAssay Description:Inhibition of human HCN1 heterologously expressed in HEK-293 cells after 30 mins by VIPR assayMore data for this Ligand-Target Pair
TargetPotassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Affinity DataIC50: 398nMAssay Description:Inhibition of human HCN1 heterologously expressed in HEK-293 cells after 30 mins by VIPR assayMore data for this Ligand-Target Pair
TargetPotassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Affinity DataIC50: 631nMAssay Description:Inhibition of human HCN1 heterologously expressed in HEK-293 cells after 30 mins by VIPR assayMore data for this Ligand-Target Pair
TargetPotassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Affinity DataIC50: 631nMAssay Description:Inhibition of human HCN1 heterologously expressed in HEK-293 cells after 30 mins by VIPR assayMore data for this Ligand-Target Pair
TargetPotassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Affinity DataIC50: 631nMAssay Description:Inhibition of human HCN1 heterologously expressed in HEK-293 cells after 30 mins by VIPR assayMore data for this Ligand-Target Pair
TargetPotassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Affinity DataIC50: 794nMAssay Description:Inhibition of human HCN4 heterologously expressed in HEK-293 cells after 30 mins by VIPR assayMore data for this Ligand-Target Pair
TargetPotassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Affinity DataIC50: 794nMAssay Description:Inhibition of human HCN4 heterologously expressed in HEK-293 cells after 30 mins by VIPR assayMore data for this Ligand-Target Pair
TargetPotassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Affinity DataIC50: 794nMAssay Description:Inhibition of human HCN4 heterologously expressed in HEK-293 cells after 30 mins by VIPR assayMore data for this Ligand-Target Pair
TargetPotassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Affinity DataIC50: 1.26E+3nMAssay Description:Inhibition of human HCN4 heterologously expressed in HEK-293 cells after 30 mins by VIPR assayMore data for this Ligand-Target Pair
TargetPotassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Affinity DataIC50: 1.26E+3nMAssay Description:Inhibition of human HCN1 heterologously expressed in HEK-293 cells after 30 mins by VIPR assayMore data for this Ligand-Target Pair
TargetPotassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Affinity DataIC50: 1.58E+3nMAssay Description:Inhibition of human HCN1 heterologously expressed in HEK-293 cells after 30 mins by VIPR assayMore data for this Ligand-Target Pair
TargetPotassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Affinity DataIC50: 1.58E+3nMAssay Description:Inhibition of human HCN4 heterologously expressed in HEK-293 cells after 30 mins by VIPR assayMore data for this Ligand-Target Pair
TargetPotassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Affinity DataIC50: 2.51E+3nMAssay Description:Inhibition of human HCN1 heterologously expressed in HEK-293 cells after 30 mins by VIPR assayMore data for this Ligand-Target Pair
TargetPotassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Affinity DataIC50: 2.51E+3nMAssay Description:Inhibition of human HCN4 heterologously expressed in HEK-293 cells after 30 mins by VIPR assayMore data for this Ligand-Target Pair
TargetPotassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Affinity DataIC50: 3.16E+3nMAssay Description:Inhibition of human HCN4 heterologously expressed in HEK-293 cells after 30 mins by VIPR assayMore data for this Ligand-Target Pair
TargetPotassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 3(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Affinity DataIC50: 3.16E+3nMAssay Description:Inhibition of human HCN3 heterologously expressed in HEK-293 cells after 30 mins by VIPR assayMore data for this Ligand-Target Pair
TargetPotassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Affinity DataIC50: 3.98E+3nMAssay Description:Inhibition of human HCN4 heterologously expressed in HEK-293 cells after 30 mins by VIPR assayMore data for this Ligand-Target Pair
TargetPotassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Affinity DataIC50: 3.98E+3nMAssay Description:Inhibition of human HCN4 heterologously expressed in HEK-293 cells after 30 mins by VIPR assayMore data for this Ligand-Target Pair
TargetPotassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Affinity DataIC50: 5.01E+3nMAssay Description:Inhibition of human HCN4 heterologously expressed in HEK-293 cells after 30 mins by VIPR assayMore data for this Ligand-Target Pair
TargetPotassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Affinity DataIC50: 5.01E+3nMAssay Description:Inhibition of human HCN4 heterologously expressed in HEK-293 cells after 30 mins by VIPR assayMore data for this Ligand-Target Pair
TargetPotassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Affinity DataIC50: 5.01E+3nMAssay Description:Inhibition of human HCN4 heterologously expressed in HEK-293 cells after 30 mins by VIPR assayMore data for this Ligand-Target Pair
TargetPotassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Affinity DataIC50: 5.01E+3nMAssay Description:Inhibition of human HCN4 heterologously expressed in HEK-293 cells after 30 mins by VIPR assayMore data for this Ligand-Target Pair
TargetPotassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 2(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Affinity DataIC50: 5.01E+3nMAssay Description:Inhibition of human HCN2 heterologously expressed in HEK-293 cells after 30 mins by VIPR assayMore data for this Ligand-Target Pair
TargetPotassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Affinity DataIC50: 6.31E+3nMAssay Description:Inhibition of human HCN4 heterologously expressed in HEK-293 cells after 30 mins by VIPR assayMore data for this Ligand-Target Pair
TargetPotassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Affinity DataIC50: 1.58E+4nMAssay Description:Inhibition of human HCN1 heterologously expressed in HEK-293 cells after 30 mins by VIPR assayMore data for this Ligand-Target Pair
TargetPotassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Affinity DataIC50: 1.58E+4nMAssay Description:Inhibition of human HCN1 heterologously expressed in HEK-293 cells after 30 mins by VIPR assayMore data for this Ligand-Target Pair
TargetPotassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Affinity DataIC50: 2.00E+4nMAssay Description:Inhibition of human HCN4 heterologously expressed in HEK-293 cells after 30 mins by VIPR assayMore data for this Ligand-Target Pair
TargetPotassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Affinity DataIC50: 2.00E+4nMAssay Description:Inhibition of human HCN4 heterologously expressed in HEK-293 cells after 30 mins by VIPR assayMore data for this Ligand-Target Pair
TargetPotassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Affinity DataIC50: 2.00E+4nMAssay Description:Inhibition of human HCN1 heterologously expressed in HEK-293 cells after 30 mins by VIPR assayMore data for this Ligand-Target Pair
TargetPotassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Affinity DataIC50: 2.51E+4nMAssay Description:Inhibition of human HCN1 heterologously expressed in HEK-293 cells after 30 mins by VIPR assayMore data for this Ligand-Target Pair
TargetPotassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Affinity DataIC50: 2.51E+4nMAssay Description:Inhibition of human HCN1 heterologously expressed in HEK-293 cells after 30 mins by VIPR assayMore data for this Ligand-Target Pair
TargetPotassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Affinity DataIC50: 3.16E+4nMAssay Description:Inhibition of human HCN4 heterologously expressed in HEK-293 cells after 30 mins by VIPR assayMore data for this Ligand-Target Pair
TargetPotassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Affinity DataIC50: 3.98E+4nMAssay Description:Inhibition of human HCN4 heterologously expressed in HEK-293 cells after 30 mins by VIPR assayMore data for this Ligand-Target Pair
TargetPotassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Affinity DataIC50: 3.98E+4nMAssay Description:Inhibition of human HCN4 heterologously expressed in HEK-293 cells after 30 mins by VIPR assayMore data for this Ligand-Target Pair